Bioinformatical assistance of selecting anti-HIV therapies: Where do we stand?

Intervirology

Volumn 55, Issue 2, 2012, Pages 108-112

  Lengauer, Thomas ^a  

^a MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

Author keywords

Bioinformatic interpretation system; Genotypic testing; HIV resistance; HIV tropism; Phenotypic testing

Indexed keywords

ANTIVIRUS AGENT; GLYCOPROTEIN GP 120; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIBIOTIC RESISTANCE; ANTIVIRAL THERAPY; BIOINFORMATICS; CLINICAL EFFECTIVENESS; GENE MUTATION; GENE SEQUENCE; GENETIC RESISTANCE; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; VIRAL TROPISM; VIRUS ENTRY; VIRUS RESISTANCE;

COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR TYPING;

EID: 84856412166     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000332000     Document Type: Review

References (28)

1. Johnson VA, et al: Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010;18:156-163.
2. Durant J, et al: Drug-resistance genotyping in HIV-1 therapy: the VIRA-graveAPT randomised controlled trial. Lancet 1999;353:2195-2199.
3. Rousseau MN, et al: Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;26:36-43.
4. Van Laethem K, et al: A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther 2002;7:123-129.
5. Rhee SY, et al: Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003;31:298-303.
6. Lengauer T, Sing T: Bioinformatics-assisted anti-HIV therapy. Nat Rev Microbiol 2006;4:790-797.
7. Lengauer T, et al: Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 2007;25:1407-1410.
8. Gazzard BG, et al: British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008;9:563-608.
9. Vandekerckhove L, et al: European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011;11:394-407.
10. Clumeck N, Pozniak A, Raffi F: European AI-graveS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008;9:65-71.
11. Vandamme AM, et al: European Recommendations for the Clinical Use of HIV Drug Resistance Testing:2011 update. AI-graveS Rev 2011;13:77-108.
12. Hirsch MS, et al: Antiretroviral drug resistance testing in adult HIV-1 infection:2008 recommendations of an International AI-graveS Society-USA panel. Top HIV Med 2008;16:266-285.
13. Palfreeman A, et al: Testing for HIV: concise guidance. Clin Med 2009;9:471-476.
14. Altmann A, et al: Keeping models that predict response to antiretroviral therapy uptodate: fusion of pure data-driven approaches with rules-based methods. Rev Antivir Ther 2009;1:A92.
15. Altmann A, et al: Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance. Antivir Ther 2007;12:169-178.
16. Altmann A, et al: Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database. J Infect Dis 2009;199:999-1006.
17. Rosen-Zvi M, et al: Selecting anti-HIV therapies based on a variety of genomic and clinical factors. Bioinformatics 2008;24:i399-i406.
18. Larder BA, et al: Clinical evaluation of the potential utility of computational modeling as an HIV treatment selection tool by physicians with considerable HIV experience. AI-graveS Patient Care ST-graveS 2011;25:29-36.
19. Saigo H, et al: Learning from past treatments and their outcome improves prediction of in vivo response to anti-HIV therapy. Stat Appl Genet Mol Biol 2011;10: article 6.
20. Prosperi MC, et al: Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. PLoS ONE 2010;5:e13753.
21. Revell A-grave, et al: Modelling response to HIV therapy without a genotype: an argument for viral load monitoring in resource-limited settings. J Antimicrob Chemother 2010;65:605-607.
22. Thielen A, Lengauer T: Geno2pheno[454] - a web server for the prediction of HIV-1 coreceptor usage from next generation sequencing data. Intervirology 2012;55:113-117.
23. Bickel S, et al: Multi-task learning for HIV therapy screening; in McCallum A, Roweis S (eds): 25th International Conference on Machine Learning (ICML 2008). Helsinki, Omnipress, 2008, pp 56-63.
24. Bogojeska J, et al: Dealing with sparse data in predicting outcomes of HIV combination therapies. Bioinformatics 2010;26:2085-2092.
25. Dunbrack RL Jr: Homology modeling in biology and medicine; in Lengauer T (ed): Bioinformatics - From Genomes to Therapies. Weinheim, Wiley-VCH, 2007, pp 297-350.
26. Bonneau R: De novo structure prediction: methods and applications; in Lengauer T (ed): Bioinformatics - From Genomes to Therapies. Weinheim, Wiley-VCH, 2007, pp 389-418.
27. Beerenwinkel N, et al: Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. J Infect Dis 2005;191:1953-1960.
28. German-Austrian DAIG-ÖAG: Antiretroviral Therapy of HIV Infection - German Austrian Guidelines (Sep. 2008) (in German). Dtsch Med Wochenschr 2009;134:S4-S15.